Blood Cholesterol Marker Flags Brain Injury Risk in Growth-Restricted Infants

Scientists have identified a cholesterol-related molecule measurable in a simple blood sample that may serve as an early warning sign of neurodevelopmental problems in infants born with intrauterine growth restriction (IUGR), a condition in which a baby grows poorly in the womb. The molecule, 24S-hydroxycholesterol (24S-HC), is a product of cholesterol metabolism, and the new study reports that its levels drop in parallel in both brain tissue and circulating blood when development is disrupted.

The research, published in the Journal of Translational Medicine, took a multi-tiered approach. The team combined astrocyte-specific knockout mice lacking the gene Abcg1, which encodes the cholesterol transporter ATP-binding cassette sub-family G member 1, with two classical IUGR animal models induced by distinct prenatal stressors, caffeine and dexamethasone. They then validated their findings in a sex-stratified clinical cohort of IUGR infants, assessing hippocampal synaptic ultrastructure, neurobehavioral performance, and 24S-HC levels in both brain tissue and peripheral blood.

The results pointed to a shared mechanism. ABCG1 deficiency or IUGR consistently produced damage to the ultrastructure of hippocampal synapses together with neurobehavioral abnormalities, and these changes were accompanied by concurrent reductions of 24S-HC in both brain tissue and peripheral blood. This consistency across different prenatal insults suggests that disrupted cholesterol homeostasis is a convergent pathway of neurodevelopmental injury rather than a side effect of any single exposure.

The clinical data strengthened the case for the biomarker. In the cohort of IUGR infants, circulating 24S-HC levels were significantly diminished in both male and female babies. Receiver operating characteristic analyses demonstrated strong predictive performance of 24S-HC for adverse neurodevelopmental outcomes, and sex-stratified logistic regression analyses confirmed that lower 24S-HC levels were independently associated with an increased risk of neurodevelopmental abnormalities.

The authors conclude that these findings establish dysregulated cholesterol metabolism as a shared mechanistic pathway underlying neurodevelopmental injury across diverse IUGR etiologies, and identify peripheral blood 24S-HC as an early, non-invasive, and predictive biomarker. Because early identification of IUGR-associated neurodevelopmental disorders has remained difficult owing to etiological heterogeneity and the lack of specific non-invasive biomarkers, a blood-based indicator could offer a new strategy for monitoring high-risk infants. The study is open access and was published on 29 October 2026.

Subject of Research: Peripheral blood 24S-hydroxycholesterol as a biomarker of neurodevelopmental disorders associated with intrauterine growth restriction

Article Title: Peripheral blood 24S-hydroxycholesterol as a trans-etiological early warning biomarker and its mechanism in IUGR-associated neurodevelopmental disorders

Article References: Zou, J., Luo, M., Xie, X., Fan, L., Hao, Y., Dai, G., Lu, M., Zhu, S., Guo, J., Wang, H., Chen, H., & Xu, D. (2026). Peripheral blood 24S-hydroxycholesterol as a trans-etiological early warning biomarker and its mechanism in IUGR-associated neurodevelopmental disorders. Journal of Translational Medicine. https://doi.org/10.1186/s12967-026-09107-9

Image Credits: AI Generated

DOI: 10.1186/s12967-026-09107-9

Keywords: intrauterine growth restriction, 24S-hydroxycholesterol, cholesterol metabolism, biomarker, neurodevelopment, ABCG1, hippocampus, prenatal stressors, astrocytes, ROC analysis, Peripheral, blood